Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 25, 2024
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2024
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 02, 2023
Lead Product(s) : Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recently published results from a Phase 1 trial conducted by ONCOtherapeutics among 28 heavily previously treated MM patients administered RUX, lenalidomide (LEN) and MP demonstrated that the therapy was well tolerated and RUX overcame refractoriness to ...
Product Name : Jakafi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recently published results from a Phase 1 trial for 28 heavily previously treated MM patients administered Ruxolitinib, lenalidomide and methylprednisolone demonstrated that the therapy was well tolerated and RUX overcame refractoriness to LEN and steroi...
Product Name : Jakafi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2021
Lead Product(s) : Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Selinexor
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Karyopharm Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 19, 2020
Lead Product(s) : Selinexor
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Karyopharm Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixazomib Citrate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2018
Lead Product(s) : Ixazomib Citrate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 12, 2017
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elotuzumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Combination Study for High Risk Multiple Myeloma Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 07, 2017
Lead Product(s) : Elotuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carfilzomib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2014
Lead Product(s) : Carfilzomib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable